Mitsubishi UFJ Trust & Banking Corp Has $7.99 Million Stock Position in Teva Pharmaceutical Industries Ltd. $TEVA

Mitsubishi UFJ Trust & Banking Corp lifted its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 2.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 476,830 shares of the company’s stock after acquiring an additional 13,077 shares during the period. Mitsubishi UFJ Trust & Banking Corp’s holdings in Teva Pharmaceutical Industries were worth $7,992,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in TEVA. Bourgeon Capital Management LLC boosted its position in Teva Pharmaceutical Industries by 100.7% during the 2nd quarter. Bourgeon Capital Management LLC now owns 723,974 shares of the company’s stock worth $12,134,000 after acquiring an additional 363,252 shares during the period. Amundi grew its position in Teva Pharmaceutical Industries by 18.5% during the first quarter. Amundi now owns 678,758 shares of the company’s stock valued at $10,080,000 after purchasing an additional 105,846 shares in the last quarter. IFM Investors Pty Ltd increased its stake in Teva Pharmaceutical Industries by 9.4% in the 2nd quarter. IFM Investors Pty Ltd now owns 226,534 shares of the company’s stock valued at $3,797,000 after buying an additional 19,447 shares during the period. Jump Financial LLC lifted its position in Teva Pharmaceutical Industries by 172.1% in the 1st quarter. Jump Financial LLC now owns 1,325,526 shares of the company’s stock worth $20,373,000 after buying an additional 838,423 shares in the last quarter. Finally, Financial Sense Advisors Inc. lifted its position in Teva Pharmaceutical Industries by 63.5% in the 1st quarter. Financial Sense Advisors Inc. now owns 405,421 shares of the company’s stock worth $6,231,000 after buying an additional 157,421 shares in the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, Director Roberto Mignone sold 200,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $24.11, for a total value of $4,822,000.00. Following the transaction, the director directly owned 495,000 shares of the company’s stock, valued at approximately $11,934,450. This trade represents a 28.78% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.49% of the company’s stock.

Teva Pharmaceutical Industries Trading Down 0.6%

Shares of NYSE:TEVA opened at $25.40 on Monday. The stock has a market capitalization of $29.13 billion, a PE ratio of -158.73, a P/E/G ratio of 1.11 and a beta of 0.70. Teva Pharmaceutical Industries Ltd. has a 1 year low of $12.47 and a 1 year high of $26.38. The firm has a fifty day moving average price of $20.39 and a 200 day moving average price of $18.24. The company has a current ratio of 1.06, a quick ratio of 0.77 and a debt-to-equity ratio of 2.45.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Wednesday, November 5th. The company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.10. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The company had revenue of $4.48 billion for the quarter, compared to analyst estimates of $4.36 billion. During the same period last year, the company earned $0.69 earnings per share. The business’s revenue was up 3.4% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.550-2.650 EPS. Analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently commented on TEVA shares. JPMorgan Chase & Co. boosted their price target on shares of Teva Pharmaceutical Industries from $26.00 to $28.00 and gave the company an “overweight” rating in a report on Thursday, November 6th. UBS Group lifted their price objective on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, October 8th. Finally, Wall Street Zen raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 11th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Teva Pharmaceutical Industries currently has an average rating of “Buy” and a consensus price target of $25.86.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.